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1. Introduction 
Periodontal lesions in chronic periodontitis are associated with a subgingival microbiota 
predominated by gram-negative anaerobic rods, spirochetes and other motile 
microorganisms (Tanner et al., 1979). Chronic periodontitis is a complex process itself 
involving periodontal microorganisms, immune system and host factors.  One reason for the 
augmented colonization of these periodontopathogens is believed to be related with a weak 
specific T helper 1-mediated immunity (Bartova et al., 2000; Breivik & Thrane, 2001; 
Wassenar et al., 1998) and, the immune response in patients with periodontal lesions may be 
inclined towards a strong T helper 2-mediated immunity. Immune functions can be 
enhanced by activating macrophages and establishing Th1 dominance (Inoue et al., 2002; 
Lee et al., 2002). The use of certain immunomodulating agents may stimulate immune 
response and activate macrophages and neutrophils. Beta-glucan (ǃ-glucan), a 
polysaccharide extracted from cell walls of Saccharomyces cerevisiae, has been found to have 
immunomodulatory effects in animals and humans (Babineau et al., 1994; Bleicher & 
Mackin, 1995; Chan et al., 2009; Engstad, 1994; Engstad et al., 2002). It increases resistance to 
bacterial infections and cancer cells while stimulating wound healing (Brown & Gordon, 
2001; Chan et al., 2009; Yun et al., 2003). Numerous studies have shown that ǃ-glucan is a 
stimulator activating phagocytosis, respiratory burst, and the production of cytokines and 
chemokines in macrophages (Kankkunen et al., 2010; Sherwood et al., 1987, Williams &  
Di Luzio, 1980). Recently, the possibility of subcutaneous injections of ǃ-glucan being able to 
modulate allergic sensitisation has been demonstrated in children (Sarinho et al., 2009). The 
authors proposed a new therapeutic strategy in allergic diseases as ǃ-glucan possesses a 
beneficial action in restoring T helper 2 function (Sarinho et al., 2009). Furthermore, besides 
its antibacterial effects, antiviral and antifungal properties of ǃ-glucan have been put 
forward (Bedirli et al., 2003; Di Luzio et al., 1980; Jung et al., 2004; Kenyon, 1983; Kernodle et 
al., 1998; Leblanc et al., 2006; Nicoletti et al., 1992; Tzianabos, 2000). The protective effect of 
ǃ-glucan has been established to Staphylococcus aureus (Di Luzio & Williams, 1978), 
Escherichia coli, Listeria monocytogenes, Mycobacterium leprae, Candida albicans (Williams et al., 
1978), Pneumocytis carinii, Leishmania donovani and Influenza virus (Jung et al., 2004).  
Transforming growth factor-beta1 (TGF-β1) plays a part in many different clinical processes, 
such as embryonal development, cellular proliferation and differentiation, wound healing, 
and angiogenesis via supression of collagenase production by fibroblasts and macrophages 
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(Edwards et al., 1987; Page, 1991) and inhibition of the release of procollagenase. Moreover, 
it increases the synthesis of extracellular matrix molecules by stimulating numerous cell 
types including fibroblasts and osteoblasts (Chen et al., 1987; Hakkinen et al., 1996; Matsuda 
et al., 1992). Expression and production of this growth factor both at periodontally healthy 
and diseased sites suggest that it contributes to maintenance of tissue integrity (Buduneli et 
al., 2001; Kuru et al., 2004a; Kuru et al., 2004b; Steinsvoll et al., 1999; Wright et al., 2003). 
Thus, these properties of TGF-β1 show its important role in the pathogenesis of periodontal 
disease and wound healing. 
Since ǃ-glucan affects immune function with quickened macrophage activation and 
establishment of T helper 1 dominance, the tissue destruction seen in periodontal disease 
may be inhibited by the usage of this immunomodulating agent.  Chaple et al. (1998) have 
reported that there was a failure of the recruitment and activation of macrophages in the 
gingival samples obtained from untreated advanced periodontitis patients, compared with 
those of patients with gingivitis. Thus, the ability of ǃ-glucan to stimulate macrophages 
seems to be very crucial. Breivik et al. (2005) evaluated the effect of ǃ-1,3/1,6 glucan on the 
progression of ligature-induced periodontal disease in animals. Their findings showed that 
orally administrated ǃ-glucan significantly reduced periodontal bone loss as measured on 
digital x-rays.  Stashenko et al. (1995) tested the effect of this biological response modifier on 
infection-stimulated alveolar bone resorption in an in vivo model.  Their findings supported 
the concept that ǃ-glucan can decrease hard and soft tissue destruction in animals. Although 
ǃ-glucan has been suggested to enhance endogenous antibacterial mechanisms in 
neutrophils and to increase the healing potential of damaged tissues (Bedirli et al., 2003; 
Browder et al., 1988, Browder et al., 1990, Stashenko et al., 1995), so far, its effect on 
periodontal tissue healing as an adjunct to nonsurgical periodontal therapy (NPT) has never 
been investigated in humans. 
The aim of this chapter is to present the results of a controlled study investigating the effects 
of NPT with an adjunctive use of systemic β-glucan on clinical, microbiological parameters 
and gingival crevicular fluid (GCF) TGF-β1 levels in chronic periodontitis patients over a 3-
month period. 
2. Materials and methods 
2.1 Study population 
Twenty subjects between 30-56 years of age were selected among chronic periodontitis 
patients who applied to the clinics of Department of Periodontology, Dental Faculty, 
Marmara University, Istanbul, Turkey. Medical and dental histories were obtained and 
intraoral examinations were carried out at pre-screening visit. Patients were diagnosed to 
have chronic periodontitis according to the clinical and radiographic findings (Armitage 
1999). Inclusion criteria were as follows: to be systemically healthy, have at least two sites 
with a probing depth ≥ 5 mm in each quadrant and radiographic evidence of moderate to 
advanced chronic periodontitis. None of the patients had received antibiotics or periodontal 
treatment within the 6 months preceeding the study. Women who were pregnant, breast-
feeding or using oral contraceptives were excluded. In addition, 10 systemically and 
periodontally healthy subjects were selected as the healthy control group. None of these 
subjects had bleeding on probing or a history of medication in the past 6 months. All 
www.intechopen.com
 
Adjunctive Systemic Use of Beta-Glucan in the Nonsurgical Treatment of Chronic Periodontitis 
 
169 
patients were non-smokers. The protocol of the study was approved by the Ethics Commitee 
of Marmara University (Number: B.30.2.MAR.0.01.00.02/AEK-232). Patients who fulfilled 
the inclusion criteria provided written informed consent and participated in the study. 
2.2 Study design 
This study was a randomized, controlled, parallel group clinical trial of 3-month duration. 
With the purpose of evaluating the adjunctive effect of β-glucan, 20 chronic periodontitis 
patients were randomly divided into 2 groups: group 1 (n=10) received NPT only, group 2 
received NPT and adjunctive β-glucan (n=10). A total of two sessions of NPT were applied 
to all patients and group 2 patients used systemic β-glucan (10 mg, 1x1) for 40 days (Fig. 1).  
 
 
SRP=scaling and root planing 
GCF= gingival crevicular fluid 
Fig. 1. Study design. 
As shown in Fig. 1, this study was consisted of four main stages including pre-screening, 
screening, baseline (Day 0) and re-evaluation (3 month - day 91). Screening examination was 
conducted to assess the patient’s eligibility for participation. The periodontal status of each 
patient was assessed by a single blinded examiner (N.N.A.). The periodontal clinical 
measurements included gingival index (Löe & Sillness, 1963), plaque index (Sillness & Löe, 
1964) and bleeding on probing. Additionally, probing depth and relative attachment level 
were measured to the nearest mm with a periodontal probe using an individual occlusal 
stent as a reference point for probe placement.  Sampling was performed from sites with a 
probing depth ≥ 5 mm and subgingival microbiological and GCF samples were collected 
from different periodontal sites.  
Patients who were eligible for the study, returned to our clinic at baseline visit for sampling 
and application of NPT. At baseline, oral hygiene instructions including brushing and 
flossing were given. Then, full mouth scaling and root planing (SRP) was performed in all 
patients using an ultrasonic scaler (Cavitron® EMZ, Switzerland) and Gracey curettes (Hu-
Friedy Ins. Co, USA) until smooth root surfaces were achieved. The group 2 patients were 
further instructed to take one capsule of ǃ-glucan (10 mg, 1x1) in the morning for 40 days. 
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At day 7, full mouth SRP was applied again in all patients. GCF samples were obtained at 
day 14. Clinical measurements and sampling procedures were repeated at 3-month re-
evaluation stage. 
2.3 Collection of GCF samples 
GCF samples were obtained at days 0 and 14, and 3 months after therapy. Two GCF samples 
from each chronic periodontitis patient were collected from mesio- and disto-buccal aspects 
of single rooted teeth exhibiting probing depth ≥ 5 mm. In the healthy control group, two 
GCF samples were collected from mesio- or disto-buccal aspect of single rooted matching 
teeth exhibiting probing depth ≤ 3 mm without any clinical sign of gingival inflammation 
and alveolar bone loss. 
Prior to GCF sampling, the selected sites were isolated with cotton rolls, saliva was removed 
using a high-power suction tip and supragingival plaque was removed using a periodontal 
probe to prevent saliva and/or plaque contamination (Griffiths et al., 1992). Paper strips 
(Periopaper; ProFlow, Inc., Amityville, NY, USA) were placed at the entrance of the crevice 
until mild resistance was felt and left in position for 30 seconds (Lamster et al., 1985). Strips 
contaminated with blood or saliva were discarded. The volumes of GCF collected were 
measured by weighing the papers, before and after sample collection, using a micro balance 
(AND 200-HM, Japan) (Kuru et al., 2004b). The weight of the fluid was converted to volume 
by assuming that the density of GCF was 1.0 (Cimasoni & Giannopoulou, 1988). The GCF 
samples were stored at -80°C until the day of laboratory analysis.  
2.4 TGF-β1 analysis in GCF 
The paper strips were allowed to thaw at room temperature for 30 minutes. GCF samples 
were eluted from the strips by placing them in 100 µl of phosphate-buffered saline (PBS) and 
stored at 4°C for up to 24 h prior to the laboratory procedures (Kuru et al., 2004a). 
GCF TGF-β1 levels were analysed by enzyme linked immunosorbent assay, using a 
commercially available Colorimetric Sandwich enzyme linked immunosorbent assay Kit 
(Quantikine DB100, R&D Systems, Minneapolis, MN, USA). In order to measure biological 
active TGF-β1, GCF samples were acidified using 20 µl 1 N HCL at room temperature for 10 
minutes. Then, the samples were neutralized by adding 20 µl 1.2 NaOH/0.5 M HEPES. The 
activated GCF samples were further analysed as described previously (Kuru et al., 2004a). 
Briefly, an aliquot of 200 µl of known concentrations (0, 31.2, 62.5, 125, 250, 500, 1000 and 
2000 pg/ml) of the activated recombinant human TGF-β1 standard and of the activated 
samples of GCF were added to the plate, which had been pre-coated with a recombinant 
human soluble receptor II which specifically binds human TGF-β1. The plate was covered 
with an adhesive strip and incubated at room temperature for 3 hours. Each well was 
aspirated and washed 3 times with 400 µl of the wash buffer provided, after which 200 µl of 
the detecting antibody (horseradish peroxidase-conjugated polyclonal antibody against 
TGF-β1) was added. The plate was again covered with an adhesive strip and incubated at 
room temperature for 1.5 hour. After washing 3 times, 200 µl of the substrate solution 
(tetramethylbenzidine containing H2O2) was added to each well and incubated at room 
temperature for 20 minutes. Following the addition of 50 µl of 2 M H2SO4 to stop the 
reaction, the absorbance at 450 nm was measured using a spectrophotometer. The 
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absorbance was also measured at 570 nm to determine any optical imperfections between 
the wells, and this value was subtracted from the absorbance at 450. A standard curve was 
prepared for each experiment and concentrations of TGF-β1 in samples were then calculated 
from this curve. The minimum detection limit of the assay kit was 4.61 pg/ml.   
2.5 Subgingival microbiological sampling 
Subgingival microbiological samples were collected at baseline and 3 months after therapy. 
The mesio- or disto-buccal site of a single-rooted tooth in the upper right quadrant 
exhibiting probing depth ≥ 5 mm was selected as the microbiological sampling site. 
Supragingival plaque was removed from the sampling site with a sterile curette followed by 
isolation using a cotton roll.  Subgingival plaque sample was collected with a standardized 
30# sterile paper point by inserting it into the crevice, and leaving in place for 10 seconds. 
Paper points contaminated with saliva or blood were discarded.  
2.6 Microbiological analysis 
The proportion of anaerobic microorganisms in the total flora was determined by 
microbiological culture method as described previously (Kuru et al., 1999; Noyan et al., 
1997; Yilmaz et al., 2002). Immediately after obtaining subgingival plaque, each sample was 
aseptically transferred into 4.5 ml of PBS and dispersed using a vortex mixer at maximal 
setting for 60 s. The dispersed samples were serially diluted and 0.2 ml portion of 10-1,  
10-2,….10-5 dilutions were spread on a solid agar medium using sterile bent glass rods. 
Trypticase soy agar plate (Oxoid, Oxoid Ltd., England) enriched with 0.0005 % hemin 
(Sigma, Sigma Chemical Co., USA), 0.00005 % menadione (Sigma), and 5 % defibrinated 
sheep blood, was inoculated for non-selective bacterial growth (Wolff et al., 1985). 
Furthermore, trypticase soy agar plate enriched with 5 % defibrinated sheep blood was used 
for cultivation for facultative anaerobic microorganisms.  
After 7 days of incubation of the supplemented trypticase soy agar plates in Gas Pak jars 
(Gas generating kit, Oxoid) in an atmosphere of 95 % H2 and 5 % CO2 at 370C, the total 
viable count was determined from the dilution giving 30-300 colonies. After 5 days of 
incubation of trypticase soy agar plate in air and 10 % CO2 at 370C, the total number of 
facultative anaerobes was determined. 
All the microbiological data were expressed as colony forming units/ml (CFU/ml). Obligate 
anaerobic bacteria was calculated as the total counts of anaerobically cultivable bacteria 
minus the total counts of facultatively anaerobic bacteria and expressed as a percentage of 
total viable count. 
2.7 Statistical analysis 
SPSS for Windows (Release 10.0, SPSS Inc., USA) was used for statistical analyses. The mean 
values for each periodontal measurement was calculated as the mean of whole mouth for 
each patient.  The mean for each periodontal parameter was also calculated separately for 
periodontal sites selected for microbial sampling with initial probing depth ≥5 mm for each 
patient.  Comparisons between the groups were carried out using the Mann-Whitney U test, 
and multiple comparisons within each group were performed using the Friedman test 
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followed by the Wilcoxon Sign test for comparisons of values between different time points. 
P values <0.05 were considered statistically significant. Lack of significance is indicated by 
not significant (NS). 
3. Results 
All of patients enrolled in this study completed the study protocol. None of the patients in 
group 2 complained of any adverse effects due to the systemic usage of ǃ-glucan. Patient 
demographics are outlined in Table 1.  
 
 Group 1 Group 2 
n 10 10 
Age (mean years ± SD) 44.5 ± 9.4 42.4 ± 7.7 
Age range 30-56 33-52 
Gender (male:female) 8:2 4:6 
Table 1. Demographic characteristics of patients participated in the study. 
3.1 Clinical findings 
The self-performed plaque control program resulted in improved oral hygiene in all patients 
supported by the finding of significant reductions in full mouth plaque index scores in both 
groups (p<0.01) (Table 2). No significant difference was found between the groups 
regarding the plaque index values (p>0.05). Significant reductions were detected in full 
mouth gingival index and bleeding on probing parameters after therapy in both groups 
(p<0.01). However, the changes in mean gingival index and bleeding on probing values of 
the group 1 were not different than those of the group 2 (p>0.05). Probing depth 
measurements at sampling sites demonstrated significant reductions from baseline to 3 
month in both groups (p<0.01). When the probing depth reduction between the groups was 
compared, there was no significant difference (p>0.05). Significant attachment gain at 
sampling sites was achieved in both groups (p<0.01) (Table 2), but intergroup comparison 
yielded no significant difference between the groups (p>0.05) (data not shown).  
 
 Group 1 Group 2 
Parameter Baseline 3 Months Baseline 3 Months 
PI(Full mouth) 2.17 ± 0.38 0.36 ± 0.23* 2.28 ± 0.31 0.44 ± 0.31* 
GI(Full mouth) 2.36 ± 0.37 0.33 ± 0.21* 2.16 ± 0.47 0.45 ± 0.42* 
BOP(%)(Full mouth) 88 ± 11 9 ± 4* 84 ± 14 10 ± 6* 
PD (mm)(Sampling sites) 5.28 ± 0.16 3.35 ± 0.33* 5.38 ± 0.14 3.49 ± 0.15* 
RAL (mm)(Sampling sites) 9.40 ± 1.14 8.18 ± 1.23* 9.56 ± 0.80 8.44 ± 0.72* 
All values are expressed as mean ± standard deviation. 
* (p<0.01), Wilcoxon Sign test 
PI=Plaque index, GI= gingival index, BOP= bleeding on probing, PD= probing depth,  
RAL= relative attachment level  
Table 2. Clinical parameters of the study groups at baseline and 3 months after treatment. 
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3.2 Biochemical findings 
GCF volume of the groups 1 and 2 showed significant decreases during the experimental 
period (p<0.05) and intragroup comparisons revealed that the decreases between days 0-14, 
14-91 and 0-91 were significant in both groups (p<0.05) (Fig. 2). However, there were no 
significant differences in the changes of GCF volume between the groups (p>0.05).  
 
* p<0.05, between days 0-14, Wilcoxon Sign test, § p<0.05, between days 0-91, Wilcoxon Sign test. 
† p<0.05, between days 14-91, Wilcoxon Sign test. 
Fig. 2. Mean GCF volume of sampling sites in study groups.  
 
¤ p<0.01, compared to groups 1 and 2, Mann-Whitney U test 
* p<0.05, respective baseline value, Wilcoxon Sign test. 
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When baseline GCF TGF-β1 concentrations of the groups 1 and 2 and the healthy group 
were compared, healthy group showed a significantly higher level of TGF-β1 than that of 
the groups 1 and 2 (p<0.01) (Fig. 3). At day 91, TGF-β1 concentration in GCF increased in the 
groups 1 and 2 when compared to their respective baseline values, but only the increase in 
the group 2 was found to be significant (p<0.05) (Fig. 3). However, no significant difference 
was found between the groups in the GCF TGF-β1 concentration level. 
3.3 Microbiological findings 
Total anaerobically grown microorganisms expressed as total viable counts in subgingival 
plaque samples before and 3 month after different treatment modalities, are given in Table 
3. NPT applied to the group 1 resulted in a decrease in total viable counts. A similar 
decrease was also noted when the group 2 patients received adjunctive β-glucan. However, 
these reductions were not significant (p>0.05). Furthermore, intergroup comparisons 
revealed no significant differences between the two groups (p>0.05). Fig. 4 demonstrates the 
proportions of obligate and facultative anaerobes of the study groups. Significant reductions 
were detected in the percentage of obligate anaerobic bacteria along with significant 
increases in the percentage of facultative anaerobic bacteria in both groups after therapy 
(p<0.01). However, no differences were found between the groups (p>0.05).  
 
Group 1 Group 2 p¥
Baseline
mean 49 88 NS
range 0.51-178 0.43-260
3 Month
mean 2 14 NS
range 0.05-6 0.06-130
pΩ NS NS
¥ Mann-Whitney U test,  ΩWilcoxon Sign test, NS=not significant 
Table 3. Total viable counts (x104 CFU/ml) of subgingival samples at baseline and after 3 months. 
 
* p<0.01, respective baseline value, Wilcoxon Sign test. 
Fig. 4. Proportions of obligate and facultative anaerobes in subgingival plaque samples of 
the groups 1 and 2.  
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This chapter presented a randomized, controlled, parallel group clinical study which was 
designed to evaluate the effects of NPT with or without adjunctive use of systemic ǃ-glucan 
on clinical, microbiological and biochemical parameters in chronic periodontitis patients 
over a 3-month period. NPT is the first stage of periodontal therapy that aims to reduce the 
number of pathogen microorganisms in periodontal pocket leading to the resolution of 
inflammatory response and arresting the progression of disease, resulting in probing depth 
reduction and attachment gain (Greenstein, 1992; Cobb, 1996; Noyan et al., 1997, Yilmaz et 
al., 2002). It is well known that the efficacy of nonsurgical therapy is related to the baseline 
probing depth, and inflammatory changes are more pronounced in deeper pockets. 
Therefore, the effectiveness of NPT and adjunctive ǃ-glucan in this study was evaluated for 
only periodontal sites with baseline probing depth ≥5 mm. Significant improvements in all 
measured clinical parameters (plaque index, gingival index, bleeding on probing, probing 
depth, relative attachment level) were observed 3 months following SRP procedure, as 
expected. Moreover, SRP supplemented with ǃ-glucan resulted in significant clinical 
outcome. However, ǃ-glucan appears to have no additional effect on clinical parameters 
recorded in the present study, as evidenced by insignificant difference between the groups. 
ǃ-glucan acts as an immunostimulant agent enhancing host-mediated immune responses to 
pathogens, especially by activating macrophages (Brown & Gordon 2001, Suzuki et al., 
2001). ǃ-glucan stimulates macrophage phagocytosis (Lee et al., 2002) and changes the 
balance from immunglobulin G1 antibodies (T helper 2 dependent antibody subclasses) 
towards a T helper 1 dependent immunglobulin G2a response (Suzuki et al., 2001). It also 
stimulates the production of T helper 1-stimulating cytokine interferon-Ǆ but suppresses 
interleukin-4 which induces T helper 2 responses (Inoue et al., 2002). Therefore, ǃ-glucan 
skew the T helper 1/T helper 2 balance towards a T helper 1-dominated response (Suzuki et 
al., 2001). The presence of a T helper 2-biased response to the periodontopathogens is 
supported by the observation that peripheral blood cells of patients release more T helper 2 
cytokines in response to periodontopathogens in vitro (Bartova et al., 2000, Wassenaar et al., 
1998). In the present study, concentration of GCF TGF-β1 increased following both therapies 
but the increase was significant only in the group 2 which received ǃ-glucan. As TGF-β1 is a 
T helper 1 stimulating cytokine, the increase of this cytokine can be explained by this 
mechanism. 
In the present study, the level of TGF-β1 in GCF samples obtained from chronic 
periodontitis patients was investigated and compared with periodontally healthy 
individuals. TGF-β1 has a very important role in the pathogenesis of periodontal diseases 
and also in wound healing. To the best of our knowledge, no data is available on 
periodontal treatment with adjunctive use of ǃ-glucan. Hence this is the first study to 
explore any effect of this immunomodulator agent on the treatment of chronic periodontitis 
patients. 
In the present study we have demonstrated that the healthy group had higher GCF TGF-β1 
concentration than the groups 1 and 2. This finding is in agreement with previous reports 
which found lower GCF TGF-β1 concentrations at inflamed sites when compared with 
healthy sites (Buduneli et al., 2001, Gürkan et al., 2005; Kuru et al., 2004a). Expression of 
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GCF constituents as concentration could result in higher levels at healthy sites where GCF 
volume is very low (Curtis et al., 1988, Emingil et al., 2000). Therefore, in healthy sites, high 
levels of TGF-β1 in GCF may be related to low GCF volume.  
TGF-β1 is a key mediator in resolution of inflammation (Sodek & Overall, 1992, Steinsvoll et 
al., 1999). This multifunctional growth factor has both pro-inflammatory and anti-
inflammatory properties (Wahl et al., 1993). Its effects on cell proliferation and 
differentiation suggest a key role for this cytokine in wound healing, tissue remodeling and 
regeneration (Sporn & Roberts, 1993). Thus, these properties of TGF-β1 indicate its 
important role in inflammatory wound healing. In the present study, concentration of GCF 
TGF-β1 increased following both therapies. After the elimination of microbial factors, as 
shown by decrease in the preposition of anaerobic species, there will be a rapid restoration 
of the periodontium; this might be the reason why the cytokine levels increased in our 
study. This increase was significant only in ǃ-glucan group between day 0 and day 91. Since 
systemic ǃ-glucan usage activates macrophages and neutrophils which produce TGF-β1 
when activated (Igarasi et al., 1993), the significant increase in group 2 might have occurred 
due the effect of ǃ-glucan. In the study of Gürkan et al. (2005), only GCF TGF-β1 levels of 
subantimicrobial dose doxycycline group was significantly higher than baseline and placebo 
group at 3 months. On the other hand, the GCF TGF-β1 concentration in the 
subantimicrobial dose doxycycline group decreased while it increased in the placebo group 
at the end of 6-month period. The authors concluded that the drug efficacy at the 
biochemical level may continue as long as the agent is used. In accordance with our results, 
Gürkan et al. (2005), have demonstrated that the level of this growth factor increased after 
resolution of inflammation. Thus, it could be hypothesized that antiinflammatory role of 
TGF-β1 may be more potent than its proinflammatory properties during healing after NPT. 
However, the levels of this cytokine at different stages of healing process needs to be 
clarified with further studies. 
The demonstration of bacterial specificity in periodontal disease allows the clinician to 
direct therapy toward the elimination or suppression of the periodontopathogens in terms 
of antimicrobial treatment. As antibiotics have important disadvantages including side 
effects, drug resistance etc., recent researches have focused on new therapeutic agents 
alternative to antibiotics. Since ǃ-glucan has been suggested to possess antimicrobial activity 
(Bedirli et al., 2003, Di Luzio et al., 1980, Nicoletti et al., 1992), we evaluated the 
microbiological effect of ǃ-glucan as an adjunct to NPT. In this study, a reduction in the 
proportion of obligate anaerobic bacteria occurred in both groups. A decrease in the number 
of anaerobic bacteria is synonimous with a successful treatment of periodontal infections 
and reflects the antimicrobial effect following NPT, as expected (Greenstein, 1992; Noyan et 
al., 1997; Yilmaz et al., 2002). But as there are no significant differences between the two 
groups, we can assume that ǃ-glucan has no additional antimicrobial effect when used 
systemically as an adjunct to NPT in patients with chronic periodontitis.  
Regarding the duration of systemic β-glucan usage, no data is available so far on its systemic 
usage in the periodontal diseases. Treatment duration with β-glucan varies from 39 days to 
90 days in animal and human studies according to the type and severity of the problem 
(Breivik et al.,2005; Kabasakal et al., 2011; Lin et al., 2011; Sarinho et al., 2009; Turunen et al., 
2011). Biagini et al. (1988) documented soft tissue healing after NPT and found precisely 
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oriented collagen bundle fibres by 30 days to 60 days. Furthermore, Magnusson et al. (1984) 
reported that repopulation of subgingival microbiota occurred between 30 to 60 days. 
Therefore, our patients in this study were put on β-glucan medication for 40 days according 
to the combination of the aforementioned data. 
5. Conclusion 
This is the first preliminary report investigating the effects of NPT plus ǃ-glucan on clinical 
parameters, subgingival microflora and GCF TGF-β1 level in patients with chronic 
periodontitis. Within its limits, systemic β-glucan used as an adjunct to NPT did not provide 
additional clinical and microbiological effects.  However, β-glucan might increase the 
concentration of TGF-β1 thereby augmenting periodontal healing potential. As ǃ-glucans 
are inexpensive and have a good margin of safety (Chan et al., 2009), their potential 
therapeutic value deserves further detailed investigations for clarifying the paucity of 
information in the literature in order to design a strategy for their possible use in clinical 
periodontal practice.  
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